Clinical trial
Safety Study of GMA161 in Patients With Idiopathic Thrombocytopenic Purpura…
NCT00244257 · Genzyme, a Sanofi Company, Industry · Terminated
Key facts
| NCT number | NCT00244257 |
|---|---|
| Title | Safety Study of GMA161 in Patients With Idiopathic Thrombocytopenic Purpura (ITP) |
| Official title | Phase I, Open-Label, Multi-center, Single-Dose, Dose-Escalating, Safety, Tolerability, Immunogenicity, Pharmacokinetics and Pharmacodynamic Study of GMA161 in Patients With Idiopathic Thrombocytopenic Purpura (ITP) |
| Lead sponsor | Genzyme, a Sanofi Company, Industry |
| Status | Terminated |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Idiopathic Thrombocytopenic Purpura |
| Intervention type | Biological |
| Interventions | GMA161 |
| Enrollment | 10 |
| Start date | Aug 1, 2005 |
| Primary completion | Jul 1, 2008 |
| Completion | Jul 1, 2008 |
| First posted | Oct 26, 2005 |
| Last update posted | Apr 9, 2015 |
| Countries | United States |
At a glance
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: